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BMS-708163 and Nilotinib restore 
synaptic dysfunction in human 
embryonic stem cell-derived 
Alzheimer’s disease models
Hisae Nishioka1,2, Norie Tooi1, Takehisa Isobe1, Norio Nakatsuji1,3 & Kazuhiro Aiba1,†
Alzheimer’s disease (AD) is the most common form of dementia. Cellular AD models derived from 
human pluripotent stem cells are promising tools in AD research. We recently developed human 
embryonic stem cell-derived AD models which overexpress mutant Presenilin1 genes, and which 
exhibit AD phenotypes, including synaptic dysfunction. In this study, we found that our AD models 
showed reduced levels of RAB3A and SV2B proteins in the pre-synapses, which is a possible cause 
of electrophysiological abnormalities. Through the screening of chemical compounds using our AD 
models, we have identified Aβ peptide inhibitors which decrease the concentration of Aβ in culture 
supernatant. Among these, BMS-708163 and Nilotinib were found to improve the expression levels 
of RAB3A and SV2B proteins and to recover the electrophysiological function in our AD models. These 
results suggest that the AD models we developed are promising materials for the discovery of AD drugs 
that target the expression of pre-synaptic proteins and synaptic function.
Alzheimer’s disease (AD) is the most common form of dementia in the elderly population. Cerebral atrophy and 
senile plaques can be found in the AD patient’s brain, where neural dysfunction and neural death are observed1,2. 
An increase in the amyloid-β 42 (Aβ 42) and Aβ 43 ratio relative to Aβ 40 is thought to be involved in plaque 
generation3,4.
AD can be categorized into sporadic and familial types: familial AD (FAD) is mainly associated with muta-
tions of three genes (the amyloid precursor protein [APP] gene, the presenilin 1 [PS1] gene and the presenilin 
2 [PS2] gene)5,6. The PS1 and PS2 proteins are related to the enzyme activity of γ -secretase that produces Aβ from 
APP7–9. In the process of Aβ generation, mutations in APP, PS1 or PS2 are involved in the increase of Aβ 42 and 
Aβ 43. These increases are thought to promote Aβ oligomerization and lead to dementia10–12. Thus, the inhibition 
of Aβ secretion is believed to represent a potential avenue for AD treatment. However, at the present time Aβ 
inhibitors have not progressed through clinical trials.
Recently, AD patient-specific induced pluripotent stem cell (iPSC) lines (AD-iPSCs) have been established as 
cellular models of AD (reviewed in ref. 13). AD-iPSCs have potential application in the discovery of new drugs 
and the investigation of disease mechanisms14,15. AD-iPSC-derived neurons show increased amounts of Aβ 42 
and increased Aβ 42/Aβ 40 ratios as AD phenotypes, but do not reproduce the electrophysiological abnormalities 
of AD16–22. In addition, it is difficult to accurately compare disease iPSCs and healthy iPSCs because they have 
different genomic backgrounds. Although healthy isogenic iPSCs can be generated from disease iPSCs with the 
use of genome-editing technologies23,24, it is not a cost-effective method for generating multiple isogenic iPSC 
lines from a single cell line.
We recently established human embryonic stem cell (hESC) lines which overexpress a mutant PS1 with the 
use of a site-directed integration system25. This gene integration system enables to generate cell lines with iden-
tical genetic backgrounds. We found that neurons derived from these hESCs showed AD phenotypes, including 
increased Aβ 42/Aβ 40 ratios and spontaneous excitatory postsynaptic current (sEPSC) abnormalities26.
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In the present study, we identified a cause of the electrophysiological abnormality in our AD models which 
overexpressed mutant PS1, screened the FDA-approved chemical libraries using our AD models, and examined 
whether the application of Aβ inhibitors can lead to the recovery of synaptic dysfunction.
Results
The decrease of RAB3A and SV2B proteins in the cellular models of AD. As described in our 
previous paper, our AD model (neurons overexpressing PS1-G378E) showed the reduction of sEPSC; however, 
the action potential amplitude and frequency did not differ between the neurons overexpressing PS1-G378E 
(PS1-G378E neurons) and those overexpressing wild-type PS1 (PS1-WT neurons)26. These facts suggested that a 
normal function of the post-synapses and an abnormal function of the pre-synapses in the PS1-G378E neurons. 
To elucidate the cause of electrophysiological abnormality in the pre-synapses of our AD models, we examined 
whether there is a difference in the level of pre-synaptic proteins in PS1-G378E and PS1-WT neurons. Western 
blot analyses were carried out using an enriched fraction of synaptic proteins (synaptosomes). We examined 10 
pre-synaptic proteins, and found an approximately 40% decrease in the expression levels of RAB3A and SV2B 
proteins in synaptosomes from PS1-G378E neurons in comparison to PS1-WT neurons (Fig. 1a), while their gene 
expression levels in PS1-G378E and PS1-WT neurons did not differ to a statistically significant extent; there was 
no difference in the expression of non-affected proteins such as SYP (synaptophysin) and SYT1 (synaptotagmin 1) 
(Supplementary Fig. S1). Furthermore, using whole cell extracts, we found that, although a decreasing tendency 
was found, the RAB3A and SV2B levels did not differ to a statistically significant extent in PS1-G378E and 
PS1-WT neurons (Fig. 1b). These results suggest that our AD model might normally regulate the gene expression 
of RAB3A and SV2B, but be defective in the translation and/or localization of the pre-synapses of these pro-
teins. Next, we examined whether there were any differences in the levels of other RAB3 or SV2 family proteins 
(Fig. 1c). The results of a Western blot analysis showed that the levels of RAB3C, RPH3A (rabphilin 3A), SV2A 
and SV2C from PS1-G378E neurons did not differ from those of PS1-WT neurons, indicating that RAB3A and 
SV2B are the only proteins from the RAB3 and SV2 families, respectively, that are abnormally expressed in the 
pre-synapses of our model.
The screening of Aβ40 inhibitors using AD model neurons. Our AD models showed increased 
Aβ 42 and Aβ 43 levels26. The increase of Aβ 42 and Aβ 43 could have resulted in the reduction of RAB3A and 
SV2B protein levels in the pre-synapses of our AD model. Thus, the inhibition of Aβ production and secretion 
may have the potential to restore the RAB3A and SV2B protein levels in the pre-synapses, and recover synaptic 
dysfunction in PS1-G378E neurons. We developed a screening system for our AD models (Fig. 2a) and screened 
chemicals that block Aβ secretion and production using libraries of known chemicals, including FDA-approved 
chemicals (see Methods). In the first screening, 246 out of 2408 chemicals tested were effective at reducing 
Aβ secretion passed (Fig. 2b). All of the γ -secretase inhibitors in the libraries were effective, including N-[N-(3,5- 
difluorophenacetyl-L-alanyl)]-S-phenyglycine t-butyl ester (DAPT), LY-450139 (Semagacestat) and BMS-708163 
(Avagacestat)27–29 (Supplementary Table S1), indicating that our AD model may be used in the discovery of novel 
γ -secretase inhibitors. In the second screening, only 127 chemicals were used out of 246 chemicals because over-
lapping chemicals in both libraries, known Aβ inhibitors including β - and γ -secretase inhibitors, and toxic chem-
icals were removed. After 2nd screening, 95 hit chemicals were identified (Fig. 2c).
Of 95 hit compounds, several FDA-approved drugs, including chemicals that have been previously reported as 
Aβ inhibitors30,31 were identified (Supplementary Table S1). Five of these FDA-approved drugs include: Nilotinib 
(a Bcr-Abl inhibitor), Pimecrolimus (a calcineurin inhibitor), Rosuvastatin Calcium (a HMG-CoA reductase 
inhibitor), Sulconazole Nitrate salt (an imidazole derivative) and Toremifene Base (a selective estrogen receptor 
modulator) were chosen for further experiments. These chemicals decreased the level of Aβ 40, but did not affect 
viability of neurons.
Next, to confirm that PS1-overexpression did not influence the screening of Aβ inhibitors, we examined 
whether the five FDA-approved drugs inhibited Aβ generation against neurons differentiated from KhES-1 (K1), 
a normal hESC line. All of these drugs were found to inhibit Aβ in a dose-dependent manner without toxicity to 
the K1-derived neurons at concentrations of less than 10 μ M (Fig. 2d,e and Supplementary Table S2). Therefore, 
PS1-overexpression did not affect the screening, indicating that our AD model, which overexpresses PS1, might 
be a promising cell source material for AD drug screening.
BMS-708163 and Nilotinib restored RAB3A and SV2B proteins in the pre-synapses. We 
next addressed whether the decrease of Aβ peptides led to the restoration of the expression levels of the 
RAB3A and SV2B proteins in the pre-synapses of our AD model. PS1-G378E neurons were treated with 
DAPT, BMS-708163, and 5 FDA-approved drugs in a different culture conditions from that used for screen-
ing. Even in different culture condition (see Methods), γ -secretase inhibitors and the 5 FDA-approved drugs 
decreased the Aβ 40 level (Fig. 3a,b) and the Aβ 42 level in our AD model (Fig. 3c,d). The levels of RAB3A 
and SV2B proteins were evaluated using synapotosomes from PS1-G378E neurons that were treated with 
these chemicals (Fig. 3e,f ). The levels of RAB3A and SV2B proteins were increased 2 and 3-fold, respec-
tively, by treatment with BMS-708163 (although RAB3A did not recover fully), but not by treatment with 
DAPT (Fig. 3e). Among the FDA-approved drugs, Nilotinib fully recovered the expression levels of the 
RAB3A and SV2B proteins (Fig. 3f ). Pimecrolimus could restore the SV2B expression level, but not the 
RAB3A level. Others did not increase the protein expression levels to a statistically significant extent. These 
data suggest that the reduction of Aβ peptides alone was not sufficient to recover the RAB3A and SV2B 
proteins.
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Figure 1. The decrease of RAB3A and SV2B protein levels in the pre-synapses of PS1-G378E neurons. 
Immunoblot analyses of the pre-synaptic proteins in the synaptosomes of PS1-G378E neurons (a) RAB3A and 
SV2B proteins in the whole fraction or synaptosomes of PS1-G378E neurons (b) and the RAB3 and SV2 family 
proteins in synaptosomes (c). β -actin (ACT) was used as an internal control. Each protein level in the PS1-WT 
neurons was defined as 1.0. **P < 0.01, as determined by Mann–Whitney U test. Neural differentiation and 
subsequent synaptosome preparation were independently performed four times (n = 4). Supplementary Fig. S4 
shows that isolation of synaptosomes was successfully carried out in all preparations. Mean ± SD. WT, PS1-wild 
type neurons; G378E, PS1-G378E neurons; DBN, drebrin; NSF, N-ethylmaleimide sensitive factor; RPH3A, 
rabphilin 3A; SNAP25, synaptosome associated protein 25 kDa; SV2, synaptic vesicle glycoprotein 2; SYN1, 
synapsin 1; SYNG1, synaptogyrin 1; SYT1, synaptotagmin 1; SYP, synaptophysin.
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BMS-708163 and Nilotinib recovered the synaptic dysfunction in PS1-G378E neurons. The 
restoration of RAB3A and SV2B proteins led us to examine whether BMS-708163 and Nilotinib could recover the 
synaptic dysfunction in PS1-G378E neurons. As reported in our previous paper26, patch-clamp analyses showed 
that the sEPSC frequency in PS1-G378E neurons was lower than that in PS1-WT neurons (Fig. 4a). There was 
an approximately 3-fold increase in the sEPSC frequencies in PS1-G378E neurons that were treated with BMS-
708163 or Nilotinib in comparison to DMSO-treated neurons (Fig. 4b). We also investigated the effects of DAPT 
and Pimecrolimus, which did not restore the RAB3A and SV2B protein levels (Fig. 4a,c). These treatments did not 
increase the sEPSC frequencies in PS1-G378E neurons. These data suggest that the restoration of both RAB3A 
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Figure 2. The screening of Aβ40 inhibitors using AD models. (a) Scheme showing the cell culture procedure 
of chemical screening. (b) The result of first screening of Aβ 40 inhibitors. The red line shows the value of the 
average ratio minus double the standard deviation (Ave - 2SD = 0.33). The compounds that reduced the Aβ 40 
ratio below Ave - 2SD value (0.33) passed the first screening. The Aβ 40 level of DMSO treatment was considered 
to be 1.0. (c) The result of second screening in Aβ 40 inhibitors. The red line indicates the criterion of hit 
compounds in the second screening (= 0.5). (d,e) The effects of Aβ inhibition (d) and cell survival (e) in dose-
response experiments using K1-derived neurons. These results show that PS1-overexpression did not influence 
the screening of Aβ inhibitors. The numerical data is shown in Supplementary Table S2. The amount of Aβ 
40 and cell viability in DMSO-treated PS1-G378E or K1 neurons was defined as 1.0. *P < 0.05, as determined 
by Steel’s test. Three independent experiments, each time in triplicates were performed (n = 3). Values are 
Mean ± SD. AraC, cytosine arabinoside; G378E, PS1-G378E neurons; K1, KhES-1-derived neurons; Nilo, 
Nilotinib; Pime, Pimecrolimus; Rosu, Rosuvastatin Calcium; Sulc, Sulconazole Nitrate salt; Tore, Toremifene 
Base.
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Figure 3. The recovery of RAB3A and SV2B protein levels in the pre-synapses of PS1-G378E neurons by 
γ-secretase inhibitors and five-hit compounds. (a,b) Aβ 40 inhibition by γ -secretase inhibitors, DAPT and 
BMS-708163 (BMS) (a) and 5-hit compounds: Nilotinib (Nilo), Pimecrolimus (Pime), Rosuvastatin Calcium 
(Rosu), Sulconazole Nitrate salt (Sulc) and Toremifene Base (Tore) (b). (c,d) Aβ 42 inhibition by γ -secretase 
inhibitors (c) and 5-hit compounds (d). The amount of Aβ 40 and Aβ 42 in PS1-WT neurons treated with DMSO 
was defined as 1.0. *P < 0.05, as determined by Steel’s test in comparison to PS1-G378E neurons treated with 
DMSO. Four independent experiments, each time in triplicates were performed (n = 4). Mean ± SD. (e,f) An 
immunoblot analysis of RAB3A and SV2B proteins in the synaptosomes of PS1-G378E neurons treated with  
γ -secretase inhibitors (e) or 5-hit compounds (f). β -actin (ACT) was used as an internal control. Each protein 
level in the DMSO-treated PS1-WT neurons was defined as 1.0. *P < 0.05, as determined by Steel’s test in 
comparison to DMSO-treated PS1-G378E neurons. The experiment was independently performed four times 
(n = 4). Mean ± SD. WT, PS1-wild type neurons; G378E, PS1-G378E neurons.
www.nature.com/scientificreports/
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Discussion
It is known that the levels of pre-synaptic proteins are downregulated in the brains of AD patients with cognitive 
impairment in comparison to the brains of healthy individuals32. The level of RAB3A protein in the hippocampus 
and frontal cortex decreases in the brains of AD patients, while the total levels of SV2 proteins (including SV2A, 
2B and 2C) in the brains of AD patients do not differ to a statistically significant extent from those in the brains of 
healthy individuals32. Consistently, the level of RAB3A protein was decreased in the synapse-enriched fraction of 
our AD model; however it was not reduced in the whole protein fraction. We found that our AD model showed 
a decrease of the levels of SV2B but not of SV2A or SV2C proteins. If our AD model mimicked the molecular 
features of AD phonotypes, the amount of SV2B protein might be reduced in the brains of AD patients. A study 
using an SV2B-specific antibody would be able to clarify this question.
Previous studies have shown decreases in the levels of other pre-synaptic proteins, such as SYP and SYT, in 
the brains of AD patients32. However, their expression levels were not decreased in our AD models. It is likely that 
this difference might be due to the different cellular conditions. Neurons are already lost in the AD brains, while 
our AD models did not show cell death. Hence, our AD model might mimic an early stage of AD progression 
(synaptic injury/dysfunction is supposed to be an early event in AD)33.
In the present study, we demonstrated that our AD model was useful in the chemical screening of previously 
reported Aβ inhibitors, including γ -secretase inhibitors and HMG-CoA reductase inhibitors27–31,34–36. Among 
these chemicals, except γ -secretase inhibitors, the molecular mechanisms of action as Aβ inhibitors are still 
unclear, but an upregulation of Aβ degrading enzymes such as neprilysin might be involved37. Our AD models 
showed increased Aβ 42 and/or Aβ 43 ratios, and synaptic abnormalities26. Hence, our AD models might be useful 
in applications to discover of Aβ 42/43 modulators and drugs that can recover synaptic dysfunction.
In addition, we showed that both BMS-708163 and Nilotinib were able to restore synaptic dysfunction in our cel-













Figure 4. The recovery of synaptic dysfunctions in PS1-G378E neurons by BMS-708163 and Nilotinib. (a) 
Representative sEPSC recordings from PS1-WT and PS1-G378E neurons cultured with DMSO and each of the 
chemicals, respectively. (b,c) The frequencies of sEPSCs after the chemical treatments that led to the recovery 
of the level of the RAB3A and SV2B proteins (b) and those that did not (c). **P < 0.01, as determined by Steel’s 
test in comparison to DMSO-treated PS1-G378E neurons. The black bars represent the median values. A dot 
indicates the sEPSC frequency of a single neuron. The sample sizes of (b) and (c) were n = 16 and 13 neurons, 
respectively. Four independent neural differentiation experiments were carried out, and sEPSC were measured 
using 3 or 4 neurons from each differentiation. See the legends of Figs 2 and 3 for abbreviations.
www.nature.com/scientificreports/
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treatment of adult leukemia38,39. A recent paper reported that tyrosine kinase inhibitors (Nilotinib and Bosutinib) 
enhanced amyloid clearance and cognitive performance in a mouse model of AD40. In addition, BMS-708163 
and Nilotinib can cross the blood-brain barrier28,41. They are therefore expected to be efficacious in the treat-
ment of AD. However, BMS-708163 has not passed clinical trials42. To date, all of the Aβ inhibitors have failed 
in clinical trials involving AD patients. It is thought that the treatments using Aβ inhibitors were administered 
too late to prevent neuronal loss in the brains of AD patients with dementia43. Thus, the administration of Aβ 
inhibitors to patients with preclinical AD or mild cognitive impairment (MCI) may cure their AD44. Our results 
suggest that BMS-708163 and Nilotinib might be effective for preventing synaptic dysfunction in preclinical 
AD or MCI patients.
Our study used neurons derived from PS1-G378E overexpressing cells along with PS1-WT hESCs. AD is 
believed to affect cholinergic neurons45. However, we did not use cholinergic neurons that were highly efficiently 
differentiated from PS1-overexpressing hESCs in this study. Only a few cell populations (0.9 ± 0.7%) were cho-
line acetyltransferase-positive neurons in our hESC-derived neurons (Supplementary Fig. S2). Future research 
should confirm these drug effects using cholinergic neurons that were induced by direct differentiation methods 
(for example46,47).
The present study could not reveal the mechanism by which the application of BMS-708163 and Nilotinib 
led to an increase in the pre-synaptic protein levels and a recovery from electrophysiological abnormalities. Aβ 
inhibition alone cannot achieve these effects. Hence, these drugs might affect an unknown target that influences 
protein expression. Future studies should address the mechanism underlying the restoration by synaptic dysfunc-
tion by BMS-708163 and Nilotinib in our AD model.
Methods
Cell culture and neural differentiation. Human ESC, KhES-1 and PS1-overexpressing hESCs derived 
from KhES-1 were cultured and differentiated as described previously26,48. Briefly, undifferentiated hESCs were 
cultured on mitomycin C-treated mouse embryonic fibroblasts in primate ES medium (ReproCELL, Japan), 
supplemented with 5 ng/ml fibroblast growth factor 2 (Wako Chemical Co., Japan). The use of the hESC lines 
conformed to the Guidelines for Derivation and Utilization of Human Embryonic Stem Cells of the Ministry of 
Education, Culture, Sports, Science, and Technology (MEXT) of Japan. We used a single clone each of PS1-WT 
and PS1-G378E hESC lines because there was no variation among any PS1-WT clones and among any PS1-
G378E clones in the protein and gene expression levels26 and the drug response to a γ -secretase inhibitor, DAPT 
(Supplementary Fig. S3).
The neural differentiation method has been previously described26. Briefly, 100 nM LDN-193189 (Cellagen 
Technology) and 1 μ M SB431542 (Sigma-Aldrich) were used for the neural induction of hESCs. Neurons differen-
tiated from hESCs were cultured in neuron maintenance medium: N2B27 medium supplemented with 10 ng/ml 
brain-derived neurotrophic factor (BDNF; PeproTech), 10 ng/ ml glial cell-derived neurotrophic factor (GDNF; 
PeproTech), 10 ng/ml neurotrophin-3 (NT-3; PeproTech) and 100 ng/mL beta-nerve growth factor (NGF; R&D 
Systems). There was no difference in the neural differentiation efficiency between PS1-WT and PS1-G378E hESC 
lines (approximately 80% NeuN-positive cells)26.
Chemical screening. The chemical screening procedure is described in Fig. 2a. Human ESC-derived neu-
rons were treated with 1 μ M cytosine arabinoside (AraC) on day 7 to eliminate dividing cells. By treatment with 
AraC, the numbers of Ki67-positive cells reduced to less than approximately 11%. After 3 days of treatment, the 
cells were replated and cultured in neuron maintenance medium with DMSO (1/20,000) as a negative control, 
800 nM DAPT (Calbiochem) as a positive control, or each chemical (5 μ M) per well for 10 days. We used two 
chemical libraries, the SCREEN-WELL FDA-approved drug library V2 Japan version (ENZO life sciences) and 
the Bioactive Compound Library (Selleck chemicals). The culture media were harvested for the measurement of 
Aβ levels. Cell viability was measured using a cell proliferation reagent (WST-1; Roche). The ratios of Aβ 40 and 
the cell viability in each chemical treatment were relative to those in DMSO treatment. The relative Aβ 40 ratio was 
adjusted based on the cell viability. The hit chemicals in the first screening were determined by the following cri-
teria: the average Aβ 40 ratios were less than the average ratio – 2 SD (mean – 2 SD). The same culture conditions 
were used for the second chemical screening (5 μ M). In the second screening, the compounds causing a greater 
than 50% reduction compared to DMSO treatment were considered as hit compounds. The dose-dependent 
effects of Nilotinib, Pimecrolimus, Rosuvastatin Calcium, Sulconazole Nitrate salt and Toremifene Base (all from 
ENZO life sciences) (0, 0.001, 0.01, 0.1, 1, and 10 μ M) were investigated using neurons derived from KhES-1.
Chemical treatment. For the chemical treatment experiments, neurons derived from hESCs were cultured 
without replating for 30 days. For the isolation of synaptosomes and the patch-clamp experiments, hESC-derived 
neurons were cultured in neuron maintenance medium with each chemical from day 10 to 30. BMS-708163 
(Selleck chemicals) (10 nM), DAPT (Calbiochem) (800 nM), Nilotinib (Cayman Chemical), Pimecrolimus 
(Cayman Chemical), Rosuvastatin Calcium (Tokyo Chemical Industry Co., Japan), Sulconazole Nitrate salt 
(SANTA CRUZ) and Toremifene Base (LKT Laboratories) (5 μ M) were used.
Amyloid-β 40 measurement. In the chemical screening, AlphaScreen reagent and a Human Amyloidβ 
1-40 (High Specificity) immunoassay kit (PerkinElmer) were used with an Enspire multimode plate reader 
(PerkinElmer). Human Amyloid β (1-40) (FL) Assay Kits (IBL, Japan) were used for the other experiments.
Isolation of synaptosomes. Synaptosomes containing functional synaptic proteins were isolated from 
neurons that had been cultured for 30 days using a Syn-PER Synaptic Protein Extraction Reagent (Thermo 
Scientific) according to the manual. For the Western blotting analysis, the synaptosome fraction was dissolved 
in RIPA buffer supplemented with 5 mM EDTA and 1× Halt Protease and Phosphatase Inhibitor Cocktail (both 
www.nature.com/scientificreports/
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from Thermo Scientific). The protein concentrations were measured using a Pierce BCA Protein Assay Kit 
(Thermo Scientific). The enrichment of synaptosomes was confirmed by the relative enhancement of the levels of 
a pre-synaptic protein (SNAP25) compared to that in whole cell extract (Supplementary Fig. S4).
Western blotting. The Western blot analyses were carried out as previously described26. PVDF membranes 
were incubated with the following primary antibodies: anti-beta actin (1:5000), anti-DBN (drebrin) (1:300), 
anti-MUNC13-4 (1:800), anti-RAB3A (1:200), anti-SV2A (1:300), anti-SV2C (1:300), anti-SYNG1 (synaptogyrin 1) 
(1:600), anti-SYT1 (synaptotagmin 1) (1:250) (all from Abcam), anti-NSF (1:750), anti-SNAP25 (1:400) (Cell 
Signaling Technology), anti-RAB3C (1:1000) (Synaptic Systems), anti-RPH3A (rabphilin 3A) (1:1000) (Santa 
Cruz), anti-SV2B (1:150), anti-SYP (synaptophysin) (1:200) (Sigma-Aldrich) or anti-SYN1 (synapsin 1) (1:200) 
(Millipore). Anti-rabbit IgG-HRP (Santa Cruz) or anti-mouse IgG-HRP (Cell Signaling Technology) were used 
as secondary antibodies. The target proteins were detected with the Novex ECL HRP Chemiluminescent Reagent 
Kit (Invitrogen) and an ImageQuant LAS 4000 system (FUJI FILM).
Quantitative reverse transcription polymerase chain reaction (qRT-PCR). Total RNA was 
extracted from hESC-derived neurons that had been cultured for 28 days using an RNeasy mini kit (QIAGEN) 
and was subjected to cDNA synthesis using the SuperScript III Reverse Transcriptase (Invitrogen). A qRT-PCR 
was carried out using SYBR Premix Ex Taq (Takara Bio Inc., Japan) and StepOnePlus (Applied Biosystems). The 
relative amount of each gene was normalized against β -actin. The primers used in the qRT-PCR were purchased 
from Takara Bio Inc.
The patch-clamp method. An electrophysiological analysis was performed as described previously26. 
Human ESC-derived neurons that had been cultured with BMS-708163, DAPT, Nilotinib or Pimecrolimus were 
randomly selected and voltage-clamped at − 70 mV. The current events that occurred in a 60-second period were 
recorded as sEPSCs.
Statistical analysis. Statistical significance was determined by the Mann-Whitney U test for differences 
between two groups, and by Steel’s test for comparisons of three or more groups. p values of < 0.05 were consid-
ered to indicate statistical significance.
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